drugset
Drugs / hematopoietic stem cell
last change Dec 2025 re-read 3 minutes ago

hematopoietic stem cell

Cell therapy

Developed for
end stage renal failure · myeloid leukemia · peripheral vascular disease
Investigated by
Northwestern University · The Affiliated Hospital of the Chinese Academy of Military Medical Sciences · University of Zurich

Trials 3

today NCT03080922 · Ph 1/2 NCT02176434 · not/applicable NCT00278603 · Ph 1
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00278603 Oct 2004 → Oct 2008 peripheral vascular disease Northwestern University Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03080922 Mar 2016 → Mar 2018 myeloid leukemia The Affiliated Hospital of the Chinese Academy of Military Medical Sciences Unknown No outcome recorded
Phase not applicable1 trial
— NCT02176434 Sep 2015 → Dec 2024 end stage renal failure University of Zurich Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as hematopoietic stem cell “Autologous Hematopoietic Stem Cell Injection” NCT00278603 ↗
2

NCT03080922 ↗

NCT02176434 ↗
Modality Cell therapy “Autologous Hematopoietic Stem Cell Injection” NCT00278603 ↗